Personalized beta-lactam dosing in cirrhosis patients with bacterial infections

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a single-center, retro-prospective observational study in China that will describe how cirrhotic patients with bacterial infections respond to beta-lactam antibiotics. Researchers will collect data on clinical presentation, laboratory results, treatments, and follow-up to build a population pharmacokinetics model. The study includes adults with cirrhosis who receive beta-lactams and have serum drug concentrations measured during therapy. A descriptive analysis will be performed to explore associations between drug levels, dosing, and outcomes. The goal is to support more personalized dosing strategies in this high-risk population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Age over 18 years Chinese patient: male or female Liver cirrhosis Diagnosed as bacterial infection Treated by β-lactams Serum concentration determined during therapy

Exclusion Criteria:

Duration of β-lactams treatment less than 48 hours Patients renal or liver function not tested before treatment started Using more than two kinds of β-lactams

Where it's running

• The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
  Nanjing, Jiangsu, China Recruiting

Study contacts

• Principal investigator: Dayu Chen — The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
• Study coordinator: Dayu Chen
• Email: cdy_pharmacy@njglyy.com
• Phone: +862583106666

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• CTX-187 first-in-human test in healthy people and people with chronic bronchiectasis and Pseudomonas infection

  This study tests CTX-187 to see if it is safe and tolerable when given as IV infusions to healthy adults and adults with chronic bronchiectasis and Pseudomonas aeruginosa infection.

  Recruiting Phase 1 Centauri Therapeutics Limited · Groningen · NCT07708116

• Vaginitis Diagnostic Algorithm Pilot Using Nanopath and Other Tests

  This study tests a new Nanopath vaginal test to see if it correctly detects vaginitis-causing pathogens in up to 1,000 people with vaginitis symptoms.

  Recruiting at 2 sites Nanopath, Inc · North Miami, Florida and 1 other locations · NCT07607470

• Testing single and multiple IV doses of JKN2501 in healthy Chinese adults

  This test gives single and multiple intravenous doses of JKN2501 to healthy Chinese adults to see if it's safe and how the body processes it.

  Recruiting Phase 1 Joincare Pharmaceutical Group Industry Co., Ltd · Changsha, Hunan · NCT07207291

• Tracking acute treatment and long-term outcomes in children with meningitis

  This registry will collect care and outcome information to see how current treatments affect short- and long-term outcomes in children under 18 with suspected meningitis in Brazil.

  Recruiting Hospital Israelita Albert Einstein · São Paulo, São Paulo · NCT07062445

• Single antibiotic versus two antibiotics for Pseudomonas bone infection

  This study will test whether one antibiotic works as well as two for adults with bone infections caused by Pseudomonas aeruginosa.

  Recruiting Centre Hospitalier de Saint-Denis · Saint-Denis, France · NCT07056881

• Improving health and quality of life for patients recovering from infective endocarditis through cardiac rehabilitation

  This study is testing if joining a cardiac rehabilitation program can help people recovering from infective endocarditis feel healthier and improve their quality of life.

  Recruiting Region Halland · Halmstad, Halland County · NCT06704048

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.